Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Compositions and methods for treatment of type 1 diabetes

A composition, technology of BHT-3021, applied in botany equipment and methods, biochemical equipment and methods, chemical instruments and methods, etc.

Pending Publication Date: 2016-03-16
TOLERION
View PDF8 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although these methods have been successful, there is still room for further improvement

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compositions and methods for treatment of type 1 diabetes
  • Compositions and methods for treatment of type 1 diabetes
  • Compositions and methods for treatment of type 1 diabetes

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0073] In type 1 diabetes, there is a strong inflammatory response that destroys islets in the pancreas, the site of insulin production and release. In type 1 diabetes (T1D), proinsulin is a major target of the adaptive immune response. The present invention provides an engineered DNA plasmid (BHT-3021) encoding proinsulin that preserves beta cell function in T1D patients by reducing insulin-specific CD8 T cells. We studied 80 subjects over the age of 18 who had been diagnosed with TlD within the past five years. Subjects were randomized 2:1 to receive intramuscular injections of BHT3021 or BHT-placebo once weekly for 12 weeks, followed by blinded monitoring of safety and immune responses. Four dose levels of BHT-3021 were evaluated: 0.3 mg, 1.0 mg, 3.0 mg, and 6.0 mg. C-peptide was used as an efficacy measure and a safety measure for the investigation. Islet-specific CD8 T cell frequencies were assessed using multimers of HLA class I monomers loaded with pancreas-derived p...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention provides compositions and methods for treating insulin-dependent diabetes mellitus in a subject comprising administration of a self-vector encoding and expressing human proinsulin.

Description

[0001] Cross References to Related Applications [0002] This application claims priority to US Provisional Application No. 61 / 818,671, filed May 2, 2013. field of invention [0003] The present invention relates to compositions and methods for treating insulin-dependent diabetes in a subject. Background of the invention [0004] One of the hallmarks of type 1 diabetes (T1D) is an inflammatory response that ultimately destroys pancreatic beta cells (a process known as insulitis). CD8 T cells against a variety of islet antigens including preproinsulin (PPI), glutamate decarboxylase (GAD), tyrosine phosphatase-like have been detected in blood and islets of individuals with T1D. Insulinoma antigen (IA2, also known as ICA512), zinc transporter ZnT8, and islet-specific glucose-6-phosphatase catalytic subunit-related protein (IGRP) (1-3). Therefore, attempts have been made to delay T1D with antigen-specific therapies, including parenteral and nasal administration of insulin (4-6...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12N15/00C12N15/63A61K48/00A61K38/28
CPCA61K48/005C12N15/85C12N2800/101C12N2800/107C12N2800/24C07K14/62A61K2039/53A61K2039/55561A61K39/0008A61K2039/572A61K2039/575A61K2039/577A61P3/10A61K48/00A61K2039/54
Inventor 巴特·O·勒普威廉·H·罗宾森保罗·乌茨海德基·葛元劳伦斯·斯坦曼
Owner TOLERION
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com